Ratings 4basebio PLC

Equities

Delayed London S.E. Other stock markets 02:59:59 2024-04-19 am EDT			5-day change	1st Jan Change
1,035 ^GBX	0.00%		+1.47%	+52.21%

Apr. 10	4basebio to supply synthetic DNA for mRNA vaccine program	AN
Apr. 10	4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.

	1st Jan change	Capi.	ESG Refinitiv
4BASEBIO PLC	+52.21%	165M	-
IQVIA HOLDINGS INC.	-1.82%	41.35B	B
LONZA GROUP AG	+41.59%	40.38B	A
MODERNA, INC.	+2.56%	39.05B	B-
CELLTRION, INC.	-12.11%	26.67B	C
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B	B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B	C+
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality